Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
Interventions: DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: SHR-A1811|DRUG: SHR-1316|DRUG: Camrelizumab|DRUG: Trophoblast cell-surface antigen 2 (TROP2) ADC|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Goserelin|DRUG: Letrozole|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Fluzoparib|DRUG: HER2 ADC
Sponsor: Fudan University